GARDP) and Entasis Therapeutics today announced the activation of the first site in South Africa as part of a global phase 3 trial of zoliflodacin for the treatment of gonorrhoea.
GARDP and BSAC sign MOU to establish framework for collaborating on education, policy and advocacy activities.
GENEVA, SWITZERLAND– The Global Antibiotic Research and Development Partnership (GARDP), Dr. Reddy’s Laboratories Ltd (Dr. Reddy’s) and Aurigene Pharmaceutical Services Limited (APSL) have signed a … GARDP, Dr. Reddy’s and Aurigene Pharmaceutical Services Limited sign MOU for antibiotic access through collaborative model
The Global Antibiotic Research and Development Partnership (GARDP), the Foundation for Innovative New Diagnostics (FIND), and the World Health Organization (WHO) have signed a memorandum of understanding to explore joint initiatives that could improve the sustainable access to antibiotics and protect them against the emergence of antimicrobial resistance (AMR), with an initial focus on sexually transmitted infections (STIs).
As the world reels from the impact of COVID-19, a new GARDP report explores how the early lessons from the COVID-19 pandemic can be applied to tackling the growing threat of antibiotic resistance.
GARDP welcomes Germany’s increased commitment to preventing and combatting global pandemics through funding to accelerate the development of new treatments for drug-resistant serious bacterial infections in hospitalized people.
GENEVA – The Global Antibiotic Research and Development Partnership (GARDP) has announced a collaboration with Bugworks Research Inc (“Bugworks”), an Indo-USA-Australian biopharmaceutical group developing new … GARDP and Bugworks Research Inc sign MOU to explore antibiotic development to tackle serious bacterial infections in high-burden countries
GARDP welcomes Japan’s commitment to the fight against drug-resistant infections, with funding that will contribute to the research and development of new treatments for the pathogens that pose the greatest threat to global health.
GARDP and the University of Queensland have announced an expansion of their partnership to tackle the growing global threat of serious bacterial infections.
GARDP has today announced an agreement with Swiss biopharmaceutical company BioVersys to explore opportunities to accelerate the research and development of antibiotics for serious bacterial infections.